Endo International (NASDAQ:ENDP) (TSE:ENL) had its target price decreased by investment analysts at Cantor Fitzgerald from $18.00 to $4.75 in a research note issued to investors on Wednesday, The Fly reports. The brokerage presently has a “neutral” rating on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 6.98% from the stock’s previous close.
A number of other brokerages have also commented on ENDP. Zacks Investment Research lowered Endo International from a “buy” rating to a “hold” rating in a research note on Wednesday, May 15th. ValuEngine lowered Endo International from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 28th. Leerink Swann lowered Endo International from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 5th. Svb Leerink lowered Endo International from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 5th. Finally, BidaskClub raised Endo International from a “hold” rating to a “buy” rating in a research note on Thursday, March 21st. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and six have assigned a buy rating to the company. Endo International presently has a consensus rating of “Hold” and an average price target of $13.57.
Shares of ENDP stock traded down $0.02 during mid-day trading on Wednesday, reaching $4.44. 64,838 shares of the stock traded hands, compared to its average volume of 3,808,919. Endo International has a 1-year low of $4.18 and a 1-year high of $18.50. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of 1.53 and a beta of 1.35.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.53 EPS for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.11. Endo International had a negative return on equity of 199.18% and a negative net margin of 18.35%. The firm had revenue of $720.00 million for the quarter, compared to analyst estimates of $692.31 million. During the same period last year, the firm posted $0.67 earnings per share. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. As a group, analysts forecast that Endo International will post 2.17 EPS for the current year.
Several institutional investors have recently bought and sold shares of the stock. Crossmark Global Holdings Inc. lifted its position in Endo International by 109.8% in the 4th quarter. Crossmark Global Holdings Inc. now owns 30,375 shares of the company’s stock valued at $222,000 after purchasing an additional 15,900 shares during the last quarter. Rhumbline Advisers lifted its position in Endo International by 25.4% in the 4th quarter. Rhumbline Advisers now owns 502,706 shares of the company’s stock valued at $3,670,000 after purchasing an additional 101,873 shares during the last quarter. LS Investment Advisors LLC bought a new stake in Endo International in the 4th quarter valued at about $59,000. Oregon Public Employees Retirement Fund bought a new stake in Endo International in the 4th quarter valued at about $76,000. Finally, Canada Pension Plan Investment Board lifted its position in Endo International by 143,723.6% in the 4th quarter. Canada Pension Plan Investment Board now owns 730,624 shares of the company’s stock valued at $5,333,000 after purchasing an additional 730,116 shares during the last quarter. 93.59% of the stock is currently owned by institutional investors.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Recommended Story: Derivative
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.